tiprankstipranks
Analyst Profile
Followed by 95 other investors
.
Patrick Dolezal

Patrick Dolezal

LifeSci Capital
Wall Street Analyst
Ranked #7,293 out of 8,050 Analysts on TipRanks (#19,712 out of 21,576 overall experts)

Success Rate

33%
36 out of 110 Profitable Transactions

Average Return

-5.40%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied Patrick Dolezal's ratings since 2020 and opened each position for the duration of 1 Year:
32.73% of your transactions would have been profitable with an average return of -5.4%

Stock Rating Distribution

137Ratings
96.35% Buy
3.65% Hold
0.00% Sell
Distribution of Patrick Dolezal's ratings

Additional Information

Main Sector:General
Geo Coverage:
United StatesUS Market
United KingdomUK Market

Best Rating

Stock:
Inventiva SA
(0RNK)
Rating Type:Buy
Dates:Mar 12, 2020 - Mar 12, 2021
Gain:407.80%
The most profitable rating made by Patrick Dolezal

Patrick Dolezal's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
FOMX
Foamix Pharma
Jan 09, 2020
Buy
Reiterated
0%
-21.18%
5
Inventiva
Jun 16, 2020
Buy
Reiterated
€25.00
(384.50% Upside)
57%
+196.54%
8
Inventiva
Mar 08, 2021
Buy
Reiterated
$25.00
(399.00% Upside)
0%
-11.65%
2
Adverum Biotechnologies
Aug 06, 2021
Hold
Assigned
$4.00
(183.69% Upside)
40%
-30.28%
15
VectivBio Holding
Apr 07, 2022
Buy
Reiterated
$22.00
(300.73% Upside)
20%
-34.70%
7
Tarsus Pharmaceuticals
May 11, 2022
Buy
Assigned
$65.00
(290.16% Upside)
40%
-11.38%
11
Larimar Therapeutics
May 12, 2022
Hold
Reiterated
$3.00
(27.12% Upside)
0%
-62.70%
5
CymaBay Therapeutics
May 13, 2022
Buy
Assigned
$7.00
(79.03% Upside)
33%
-10.28%
9
Rocket Pharmaceuticals
May 19, 2022
Buy
Assigned
$33.00
(88.46% Upside)
48%
+2.53%
27
Tenaya Therapeutics
Jun 16, 2022
Buy
Initiated
$25.00
(385.44% Upside)
100%
+5.30%
1
List of latest recommendations made by Patrick Dolezal. Click to expand and see Patrick Dolezal's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More